Aclaris Therapeutics (ACRS) Assets Average (2015 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Assets Average of $179.6 million for Q1 2026, down 14.16% year-over-year from $209.2 million in Q1 2025, and up 6.9% quarter-over-quarter from $168.0 million in Q4 2025.
Aclaris Therapeutics (ACRS) Assets Average (2015 - 2026) Analysis & Trends
Aclaris Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $179.6 million for Q1 2026.
- In Q1 2026, Assets Average fell 14.16% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $179.6 million (down 14.16% YoY), while the FY2025 annual figure was $190.4 million, down 8.84% from the prior year.
- Assets Average for Q1 2026 stood at $179.6 million, up from $168.0 million in the prior quarter.
- The five-year high for Assets Average was $272.8 million in Q3 2022, with the low at $167.6 million in Q2 2024.
- The 5-year median for Assets Average is $207.9 million (2023), against an average of $211.4 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average soared 105.76% in 2022, then retreated 27.98% in 2024.
- Aclaris Therapeutics' Assets Average stood at $261.1 million in 2022, then decreased by 20.39% to $207.9 million in 2023, then dropped by 3.14% to $201.4 million in 2024, then slipped by 16.57% to $168.0 million in 2025, then grew by 6.9% to $179.6 million in 2026.
- Business Quant data shows ACRS's Assets Average at $179.6 million in Q1 2026, $168.0 million in Q4 2025, and $182.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 189.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189.21 Mn |
| Mar 31, 2026 | 179.59 Mn |
| Dec 31, 2025 | 168.00 Mn |
| Sep 30, 2025 | 182.34 Mn |
| Jun 30, 2025 | 193.62 Mn |
| Mar 31, 2025 | 209.21 Mn |
| Dec 31, 2024 | 201.36 Mn |
| Sep 30, 2024 | 171.73 Mn |
| Jun 30, 2024 | 167.57 Mn |
| Mar 31, 2024 | 185.74 Mn |
| Dec 31, 2023 | 207.88 Mn |
| Sep 30, 2023 | 227.00 Mn |
| Jun 30, 2023 | 232.68 Mn |
| Mar 31, 2023 | 242.15 Mn |
| Dec 31, 2022 | 261.11 Mn |
| Sep 30, 2022 | 272.80 Mn |
| Jun 30, 2022 | 252.25 Mn |
| Mar 31, 2022 | 238.87 Mn |
| Dec 31, 2021 | 257.35 Mn |
| Sep 30, 2021 | 275.77 Mn |